CBUS · Cibus, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 1, 2023; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Q2 revenue rose 35% YTD on biofragrance ramp; rice commercial launch in Latin America pushed from late 2027 to 2028; net cash burn guidance raised to ~$35M exiting 2026; EU finalized rules treating gene-edited crops with no foreign DNA as conventional, and Interoc relationship expanded from two to five rice traits.
- + YTD revenue up 35% YoY driven by Sustainable Ingredients program.
- + Biofragrance opportunity sized at $20-40M peak annual revenue.
- + Interoc rice relationship expanded from two to five traits, deepening the pipeline model.
- + EU finalized rules treating most gene-edited crops (no foreign DNA) as conventional, opening a major market.
- + FDA completed review of altered-lignin alfalfa trait with no further questions; USDA-APHIS confirmed Cibus traits are not regulated articles.
- − Latin American rice commercial launch timing pushed from late 2027 to 2028.
- − Cash of $20.4M only funds operations into early Q1 2027 absent new financing.
- − Non-cash royalty liability interest expense rose to $9.5M (from $8.7M) and remains the largest gap between operating and net loss.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBUS
this stock
Cibus, Inc.
|
$119.99M | -9.8% | -14.6% | — | 4.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 1, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBUS | -0.6% | -17.4% | -36.7% | -3.1% | -9.8% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +0.5% | -15.6% | -54.5% | -2.7% | -21.9% |